Trial Information
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)
Inclusion Criteria:
1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the
current World Health Organisation Classification, from 2001 to 2007.
2. Any stage of disease.
3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
4. Age at least 18 years.
5. Availability of tissue biopsy at diagnosis for a possible centralized revision.
6. Availability of data on clinical involvement, laboratory, treatment and follow up.
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Principal Investigator
Massimo Federico, MD
Investigator Role:
Study Director
Investigator Affiliation:
Oncologia II Azienda Ospedaliera Universitaria di Modena
Authority:
Italy: The Italian Medicines Agency
Study ID:
IIL_ProDLBCL
NCT ID:
NCT01478269
Start Date:
May 2009
Completion Date:
May 2011
Related Keywords:
- B-Cell Lymphomas
- Aggressive B-cell lymphoma
- R-CHOP
- Aggression
- Lymphoma
- Lymphoma, B-Cell